These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37691348)
1. Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer. Vaishampayan U Chin Clin Oncol; 2023 Dec; 12(6):61. PubMed ID: 37691348 [No Abstract] [Full Text] [Related]
2. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis. Zhang X; Zhang G; Wang J; Bi J Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752 [TBL] [Abstract][Full Text] [Related]
4. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH Molecules; 2020 May; 25(10):. PubMed ID: 32456317 [TBL] [Abstract][Full Text] [Related]
5. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
6. An up-to-date evaluation of darolutamide for the treatment of prostate cancer. Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506 [No Abstract] [Full Text] [Related]
8. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096 [TBL] [Abstract][Full Text] [Related]
9. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656 [TBL] [Abstract][Full Text] [Related]
10. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. Westaby D; Fenor de La Maza MLD; Paschalis A; Jimenez-Vacas JM; Welti J; de Bono J; Sharp A Annu Rev Pharmacol Toxicol; 2022 Jan; 62():131-153. PubMed ID: 34449248 [TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Prostate Cancer Treatment and Drug Discovery. Nevedomskaya E; Baumgart SJ; Haendler B Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647 [TBL] [Abstract][Full Text] [Related]
12. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393 [TBL] [Abstract][Full Text] [Related]
13. New approaches to targeting the androgen receptor pathway in prostate cancer. Velho PI; Bastos DA; Antonarakis ES Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptor antagonists for prostate cancer therapy. Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562 [TBL] [Abstract][Full Text] [Related]
15. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485 [TBL] [Abstract][Full Text] [Related]